Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites

Table 1 Patients’ characteristics, n (%)

		All (n = 124)	HAB (n = 26)	LAB (n = 98)	P value
Age (years)	Median (range)	70 (23-87)	71.5 (38-86)	70 (23-87)	0.9211
Sex	Male	82 (66)	14 (54)	68 (69)	0.1641
PS	0	44 (35)	1 (4)	43 (44)	< 0.0001
	1	60 (48)	16 (62)	44 (45)
	2 or 3	20 (16)	9 (35)	11 (11)
Location	Esophago-gastric junction	20 (16)	1 (4)	19 (19)	0.0716
	Gastric	104 (84)	25 (96)	79 (81)
Gastrectomy	Yes	34 (27)	5 (19)	29 (30)	0.3345
Pathology	Diffuse type	75 (60)	24 (92)	51 (52)	0.0009
Number of metastatic organs	2 or more	62 (50)	15 (58)	47 (48)	0.5086
Liver metastasis	Yes	38 (31)	4 (15)	34 (35)	0.0921
Peritoneum dissemination	Yes	75 (60)	25 (96)	50 (51)	< 0.0001
Ascites	Yes	47 (38)	26 (100)	21 (21)	< 0.0001
High ascites burden	Yes	26 (21)	26 (100)	0	< 0.0001
Regimen	SOX	67 (54)	8 (31)	59 (60)	0.0037
	FOLFOX	51 (41)	18 (69)	33 (34)
	CAPOX	6 (5)	0	6 (6)
PD-L1 CPS	Less than 1	24 (19)	10 (38)	14 (14)	0.0082
	1 ≤ CPS < 5	36 (29)	6 (23)	29 (30)
	5 or more	45 (36)	5 (19)	41 (42)
	Unknown	19 (15)	5 (19)	14 (14)
MSI	MSI-high	5 (4)	0	5 (5)	0.3489
	MSS	74 (60)	18 (69)	56 (57)
	Unknown	45 (36)	8 (31)	37 (38)
CLDN 18.2	Positive	14 (11)	4 (15)	10 (10)	0.0767
	Negative	29 (23)	2 (8)	27 (28)
	Unknown	81 (65)	20 (77)	61 (62)

PS: Performance status; CPS: Combined positive score; MSI: Micro satellite instability; MSS: Microsatellite stable; HAB: High ascites burden; LAB: Low ascites burden.